Outcome of Board Meeting pursuant to Regulation 30, 32 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Integrated Proteins Limited's board, meeting on 14th August 2025, approved the unaudited standalone financial results for Q1 FY26 (quarter ended 30 June 2025). Revenue from operations came in at NIL, compared with Rs. 2,148.67 lakh in the same quarter last year — a 100% year-on-year drop. Other income of Rs. 4.72 lakh kept total income at Rs. 4.72 lakh. The company reported a marginal net profit of Rs. 0.01 lakh (versus a loss of Rs. 0.07 lakh in Q1 FY25). The auditor, B.B. Gusani & Associates, issued an unqualified review report. The board also confirmed there has been no deviation in the use of proceeds from the preferential issue (Rs. 1,744.88 lakh raised in January-February 2025).
The complete absence of operating revenue in Q1 FY26 is a major red flag for shareholders, indicating either a halt in core business activity or a timing issue with sales recognition. Despite a small profit on paper, the lack of revenue raises serious concerns about the company's business continuity and near-term prospects, which could weigh negatively on the stock.